Catalyst Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Catalyst Pharmaceuticals
CPRX Stock  USD 21.28  0.26  1.24%   
Catalyst Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Catalyst Pharmaceuticals' valuation are provided below:
Gross Profit
446.5 M
Profit Margin
0.3691
Market Capitalization
2.6 B
Enterprise Value Revenue
3.7746
Revenue
534.6 M
We have found one hundred twenty available fundamental signals for Catalyst Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Catalyst Pharmaceuticals prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 2.6 B in 2025. Enterprise Value is likely to rise to about 2.1 B in 2025

Catalyst Pharmaceuticals Total Revenue

516.32 Million

Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 311.4 M or Operating Income of 204.9 M, as well as many indicators such as Price To Sales Ratio of 4.78, Dividend Yield of 0.0 or PTB Ratio of 3.23. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Catalyst Stock
Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Catalyst Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets894 M851.4 M217.1 M
Slightly volatile
Total Stockholder Equity764 M727.6 M184.1 M
Slightly volatile
Cash543.4 M517.6 M126.5 M
Slightly volatile
Other Assets1.091.154.7 M
Slightly volatile
Cash And Short Term Investments543.4 M517.6 M140.2 M
Slightly volatile
Common Stock Shares Outstanding131.2 M124.9 M82.3 M
Slightly volatile
Liabilities And Stockholders Equity894 M851.4 M217.1 M
Slightly volatile
Other Stockholder Equity464.4 M442.3 M192.9 M
Slightly volatile
Total Liabilities130 M123.8 M33 M
Slightly volatile
Total Current Assets654.8 M623.6 M164.6 M
Slightly volatile
Other Current Liabilities108.4 M103.2 M24.7 M
Slightly volatile
Total Current Liabilities126.7 M120.7 M30.3 M
Slightly volatile
Property Plant And Equipment Net3.8 M3.6 M1.3 M
Slightly volatile
Accounts Payable17.4 M16.6 M4.7 M
Slightly volatile
Non Current Assets Total239.2 M227.8 M52.5 M
Slightly volatile
Common Stock Total Equity66.6 K120.8 K81.1 K
Slightly volatile
Property Plant And Equipment Gross4.9 M4.7 M1.5 M
Slightly volatile
Common Stock72.2 K121 K81.6 K
Slightly volatile
Property Plant Equipment1 M974 K566.2 K
Slightly volatile
Other Current Assets22.1 M21 M5.9 M
Slightly volatile
Net Receivables68.7 M65.5 M17.3 M
Slightly volatile
Other Liabilities17 M16.2 M7 M
Slightly volatile
Non Current Liabilities Total2.7 M3.1 M2.9 M
Slightly volatile
Net Tangible Assets323.5 M308.1 M121.1 M
Slightly volatile
Capital Surpluse169.1 M288 M167.1 M
Slightly volatile
Non Current Liabilities Other299.2 K315 K2.3 M
Pretty Stable
Current Deferred Revenue796.4 K838.4 K4.1 M
Slightly volatile
Net Invested Capital764 M727.6 M208.9 M
Slightly volatile
Net Working Capital528.1 M502.9 M158.6 M
Slightly volatile
Capital Stock117.2 K121 K105.3 K
Slightly volatile
Short and Long Term Debt Total2.8 M3.2 M1.5 M
Slightly volatile
Capital Lease Obligations2.8 M3.2 M1.7 M
Slightly volatile
Short Term Debt320 K402 K298.1 K
Pretty Stable

Catalyst Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses311.4 M296.6 M87.4 M
Slightly volatile
Research Development13.9 M12.6 M16.9 M
Slightly volatile
Total Operating Expenses239.2 M227.8 M69.9 M
Slightly volatile
Depreciation And Amortization39.7 M37.8 M7.1 M
Slightly volatile
Selling General Administrative69.7 M66.4 M21.6 M
Slightly volatile
Interest Income1.9 M1.8 M882.8 K
Slightly volatile
Net Interest Income16.9 M16.1 M3.6 M
Slightly volatile
Reconciled Depreciation39.7 M37.8 M6.6 M
Slightly volatile
Selling And Marketing Expenses116.9 M111.3 M26.7 M
Slightly volatile

Catalyst Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow144.5 M137.6 M69.5 M
Slightly volatile
Depreciation39.7 M37.8 M7.1 M
Slightly volatile
Capital Expenditures528.2 K556 K12.6 M
Slightly volatile
End Period Cash Flow543.4 M517.6 M126.5 M
Slightly volatile
Stock Based Compensation23.4 M22.3 M6 M
Slightly volatile
Net Borrowings4 M4.5 M4.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.785.0275202
Slightly volatile
PTB Ratio3.233.397623.7315
Slightly volatile
Days Sales Outstanding45.3548.60139.6677
Slightly volatile
Book Value Per Share6.456.14251.746
Slightly volatile
Average Payables4 M3.8 M2.6 M
Slightly volatile
Stock Based Compensation To Revenue0.0430.04533.6266
Slightly volatile
Capex To Depreciation0.0140.01471.9812
Pretty Stable
PB Ratio3.233.397623.7315
Slightly volatile
EV To Sales3.783.9815184
Slightly volatile
Inventory Turnover3.353.5231202
Slightly volatile
Days Of Inventory On Hand59.8510436.9834
Slightly volatile
Payables Turnover3.414.1492.8829
Slightly volatile
Sales General And Administrative To Revenue0.130.13516.2321
Slightly volatile
Research And Ddevelopement To Revenue0.02440.025720.2653
Slightly volatile
Capex To Revenue0.00110.00110.1242
Pretty Stable
Cash Per Share4.594.36911.3715
Slightly volatile
Days Payables Outstanding83.5787.97228.6 K
Slightly volatile
Income Quality0.771.46321.0224
Slightly volatile
Intangibles To Total Assets0.180.1840.1188
Slightly volatile
Current Ratio4.915.16758.7841
Slightly volatile
Tangible Book Value Per Share5.064.81991.4427
Slightly volatile
Receivables Turnover10.297.510111.1223
Slightly volatile
Graham Number14.5213.8284.7932
Slightly volatile
Shareholders Equity Per Share6.456.14251.746
Slightly volatile
Debt To Equity0.00710.00440.0079
Pretty Stable
Capex Per Share0.00450.00470.1184
Slightly volatile
Graham Net Net4.013.82121.1678
Slightly volatile
Average Receivables7.8 M7.4 M5.7 M
Slightly volatile
Revenue Per Share4.364.15111.1189
Slightly volatile
Interest Debt Per Share0.02830.02690.0139
Slightly volatile
Debt To Assets0.00590.00370.0064
Pretty Stable
Operating Cycle81.2215256.2917
Slightly volatile
Price Book Value Ratio3.233.397623.7315
Slightly volatile
Days Of Payables Outstanding83.5787.97228.6 K
Slightly volatile
Ebt Per Ebit0.81.10831.0025
Very volatile
Company Equity Multiplier1.41.17011.2947
Slightly volatile
Long Term Debt To Capitalization0.00420.00440.0084
Very volatile
Total Debt To Capitalization0.0070.00440.0078
Pretty Stable
Debt Equity Ratio0.00710.00440.0079
Pretty Stable
Quick Ratio4.765.00568.708
Slightly volatile
Net Income Per E B T1.070.75780.9661
Very volatile
Cash Ratio4.074.28874.6606
Very volatile
Days Of Inventory Outstanding59.8510436.9834
Slightly volatile
Days Of Sales Outstanding45.3548.60139.6677
Slightly volatile
Cash Flow Coverage Ratios71.4675.2221146
Pretty Stable
Price To Book Ratio3.233.397623.7315
Slightly volatile
Fixed Asset Turnover13713795.1769
Slightly volatile
Debt Ratio0.00590.00370.0064
Pretty Stable
Cash Flow To Debt Ratio71.4675.2221146
Pretty Stable
Price Sales Ratio4.785.0275202
Slightly volatile
Asset Turnover0.420.57760.2929
Slightly volatile
Price Fair Value3.233.397623.7315
Slightly volatile

Catalyst Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.6 B2.5 B707.6 M
Slightly volatile
Enterprise Value2.1 B2 B579.7 M
Slightly volatile

Catalyst Fundamental Market Drivers

Forward Price Earnings11.4679
Cash And Short Term Investments517.6 M

Catalyst Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Catalyst Pharmaceuticals Financial Statements

Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue838.4 K796.4 K
Total Revenue491.7 M516.3 M
Cost Of Revenue68.8 M72.3 M
Stock Based Compensation To Revenue 0.05  0.04 
Sales General And Administrative To Revenue 0.14  0.13 
Research And Ddevelopement To Revenue 0.03  0.02 
Revenue Per Share 4.15  4.36 
Ebit Per Revenue 0.40  0.42 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY